Immunoreactivity of p53, Ki-67, and bcl-2 in oncocytic adenomas and carcinomas of the thyroid gland

被引:23
作者
Müller-Höcker, J [1 ]
机构
[1] LMU, Inst Pathol, D-80337 Munich, Germany
关键词
p53; Ki-67; bcl-2; oxyphil neoplasms; thyroid;
D O I
10.1016/S0046-8177(99)90246-0
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
To analyze relevant factors of neoplastic transformation in oncocytic neoplasms of the thyroid, expression of p53, Ki-67, and bcl-2 has been studied in oncocytic carcinomas (n = 17) and compared with results obtained in oncocytic adenomas (n = 20). P53 protein accumulation was found immunohistochemically in 75% of the oncocytic adenomas (15 of 20) and 88% of the oncocytic carcinomas (15 of 17). Eight of 17 of the carcinomas (47%), but only 3 of the 20 adenomas (15%), showed nuclear p53 accumulation in more than 10% of the cells, mostly in a focal pattern. Ki-67 expression also differed significantly between adenomas and carcinomas. The median of Ki-67-positive cells was 12/10 high-power fields (HPF) for adenomas and 76/10 HPF for carcinomas (P < .001). Furthermore, metastatic carcinomas had a significantly higher Ki-67 positivity than nonmetastasized carcinomas (164/10 HPF v 42/10 HPF, P < .05). Bcl-2 immunohistochemistry showed a constantly positive reaction in normal thyroid tissue. In contrast, bcl-2 protein was not detected in most of the adenomas (70%) and carcinomas (76%). In conclusion, p53 protein and Ki-67 is more prevalent in oncocytic carcinomas than in oncocytic adenomas of the thyroid, indicating that these factors may be involved in the progression of oncocytic neoplasms in the thyroid. In contrast, loss of bcl-2 appears to be an early event in the formation of oncocytic neoplasms of the thyroid. Its importance for malignant transformation is, however, unclear. (C) 1999 by W.B. Saunders Company.
引用
收藏
页码:926 / 933
页数:8
相关论文
共 64 条
  • [1] ASSOCIATION OF P53 PROTEIN EXPRESSION WITH TUMOR-CELL PROLIFERATION RATE AND CLINICAL OUTCOME IN NODE-NEGATIVE BREAST-CANCER
    ALLRED, DC
    CLARK, GM
    ELLEDGE, R
    FUQUA, SAW
    BROWN, RW
    CHAMNESS, GC
    OSBORNE, CK
    MCGUIRE, WL
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1993, 85 (03) : 200 - 206
  • [2] CHROMOSOME-17 DELETIONS AND P53 GENE-MUTATIONS IN COLORECTAL CARCINOMAS
    BAKER, SJ
    FEARON, ER
    NIGRO, JM
    HAMILTON, SR
    PREISINGER, AC
    JESSUP, JM
    VANTUINEN, P
    LEDBETTER, DH
    BARKER, DF
    NAKAMURA, Y
    WHITE, R
    VOGELSTEIN, B
    [J]. SCIENCE, 1989, 244 (4901) : 217 - 221
  • [3] Baretton GB, 1996, CANCER, V77, P255, DOI 10.1002/(SICI)1097-0142(19960115)77:2<255::AID-CNCR6>3.0.CO
  • [4] 2-L
  • [5] BARTEK J, 1991, ONCOGENE, V6, P1699
  • [6] BATSAKIS JG, 1995, ADV ANAT PATHOL, V2, P71
  • [7] P53 IMMUNOHISTOCHEMISTRY - A WORD OF CAUTION
    BATTIFORA, H
    [J]. HUMAN PATHOLOGY, 1994, 25 (05) : 435 - 437
  • [8] The oncocytic variant of papillary carcinoma of the thyroid: A clinicopathologic study of 15 cases
    Berho, M
    Suster, S
    [J]. HUMAN PATHOLOGY, 1997, 28 (01) : 47 - 53
  • [9] BCL-X, A BCL-2-RELATED GENE THAT FUNCTIONS AS A DOMINANT REGULATOR OF APOPTOTIC CELL-DEATH
    BOISE, LH
    GONZALEZGARCIA, M
    POSTEMA, CE
    DING, LY
    LINDSTEN, T
    TURKA, LA
    MAO, XH
    NUNEZ, G
    THOMPSON, CB
    [J]. CELL, 1993, 74 (04) : 597 - 608
  • [10] P53 ACCUMULATION IN OVARIAN CARCINOMAS AND ITS PROGNOSTIC IMPLICATIONS
    BOSARI, S
    VIALE, G
    RADAELLI, U
    BOSSI, P
    BONOLDI, E
    COGGI, G
    [J]. HUMAN PATHOLOGY, 1993, 24 (11) : 1175 - 1179